PT - JOURNAL ARTICLE AU - Pristner, Manuel AU - Wasinger, Daniel AU - Seki, David AU - Klebermaß-Schrehof, Katrin AU - Berger, Angelika AU - Berry, David AU - Wisgrill, Lukas AU - Warth, Benedikt TI - Neuroactive metabolites and bile acids are altered in extremely premature infants with brain injury AID - 10.1101/2023.05.17.23290088 DP - 2023 Jan 01 TA - medRxiv PG - 2023.05.17.23290088 4099 - http://medrxiv.org/content/early/2023/05/24/2023.05.17.23290088.short 4100 - http://medrxiv.org/content/early/2023/05/24/2023.05.17.23290088.full AB - The gut microbiome has been associated with pathological neurophysiological evolvement in extremely premature infants suffering from brain injury. The exact underlying mechanism and its associated metabolic signatures in infants are not fully understood. To decipher metabolite profiles linked to neonatal brain injury, we investigated the longitudinal fecal and plasma metabolome of 51 extremely premature infants using LC-HRMS-based untargeted metabolomics. This was expanded by an investigation of bile acids and amidated bile acid conjugates in feces and plasma by LC-MS/MS-based targeted metabolomics. The resulting data was integrated with 16S rRNA gene amplicon gut microbiome profiles as well as patient cytokine, growth factor and T-cell profiles. We identified an early onset of differentiation in neuroactive metabolites and bile acids between infants with and without brain injury. We detected several bacterially-derived bile acid amino acid conjugates and secondary bile acids in the plasma already three days after delivery, indicating the early establishment of a metabolically active gut microbiome. These results give new insights into the early life metabolome of extremely premature infants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by an inter-university cluster project grant between the University ofVienna and the Medical University of Vienna (PreMiBraIn). The European Research Council (Starting grant: FunKeyGut 741623). The Austrian Science Fund (FWF; P27831-B28).The ERC grant (EXPOMET; ID: 101043321). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the Medical University of Vienna gave ethical approval for this work (Ethics number 1348/2017)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors